Skip to main navigation
Krystal Biotech, Inc
  • Focus
    • Our Focus
    • Pipeline
    • Dystrophic EB
    • Netherton Syndrome
    • TGM1-deficient ARCI
    • Cystic Fibrosis
    • Aesthetic Skin Conditions
    • Chronic Skin Diseases
  • Patients and Families
    • Our Gene Therapy
    • Our Star-D Platform
    • Our Targets
    • Patient Advocacy
  • Medical Professional
  • About Us
  • Investors
    • Overview
    • News Releases
    • Events and Presentations
    • Corporate Governance
    • Analyst Coverage
    • Investor FAQs
    • SEC Filings
    • Stock Quote & Chart
    • Email Alerts
    • Select Scientific Publications
  • Contact
    • Careers
    • Contact Us
Contact Us

Investors

Investor Relations
  • Overview
  • News Releases
  • Events
  • Corporate Governance
  • Analyst Coverage
  • Investor FAQs
  • SEC Filings
  • Stock Quote
  • Email Alerts
  • Scientific Publications

Scientific Publications

Scientific Publications
Topical Herpesvirus Gene Therapy Enters Final Lap | Nature Biotechnology
SID 2022 Presentation – B-VEC – GEM-3 Safety and Immunogenicity
SID 2022 – B-VEC – GEM-3 Safety and Immunogenicity
In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial | Nature Medicine
GEM-3: A Phase 3 Study of Beremagene Geperpavec (B-VEC), an Investigational, Topical Gene Therapy, for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)
ASDS 2021 – KB303 – In vitro and In vivo preclinical
NACFC 2021 – KB407 – Nonclinical Pharmacology
Sept 2021 - Marinkovich - BVEC talk for DEBRA
Sept 2021 - BVEC - DEBRA Intl Corneal Scratch Model
ASGCT 2021 - KB500s - vectorized antibodies in vitro and in vivo data
SID 2021 - B-VEC - GEM-1/2 Safety Review
SID 2021 - KB301 - Phase 1 Safety
April 2021 - KB105 - Freedman et al. JID publication
ASDS 2020 - KB301 - Preclinical (in vitro and in vivo)
ASGCT 2020 - KB407 - In Vitro Data
SID 2020 - KB105 - Phase 1 Data
SID 2020 - B-VEC - Complete GEM-1/2 Data
Oct 2019 - B-VEC - GEM-1/2 Update
June 2019 - GEM-2 Update
SID 2019 - KB105 - Preclinical (in vitro)
SID 2019 - KB105 - Preclinical (in vivo)
SID 2019 - KB104 - Preclinical
IID 2018 - B-VEC - Preclinical (in vivo)
EB 2017 - B-VEC - Preclinical (in vitro and in vivo)

Quick Links

Focus
Patients and Families
Medical Professionals
About Us
Investors
Contact


© Krystal Biotech All Rights Reserved

Krystal Biotech, Inc.

2100 Wharton St. #701
Pittsburgh, PA 15203
412-586-5830
inquiries@krystalbio.com